| Literature DB >> 26228207 |
Xin Wang, Fang Yang, Michiel L Bots, Wei-Ying Guo, Bing Zhao, Arno W Hoes, Ilonca Vaartjes1.
Abstract
BACKGROUND: The metabolic syndrome is a clustering of metabolic abnormalities and has been associated with increased risk of type 2 diabetes mellitus and cardiovascular disease. This study aimed to estimate the prevalence of the metabolic syndrome among employees in Northeast China.Entities:
Mesh:
Year: 2015 PMID: 26228207 PMCID: PMC4717958 DOI: 10.4103/0366-6999.161337
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Definitions of the metabolic syndrome
| Risk factors | Revised NCEP ATP III 2005 | IDF 2006 | CDS 2004 |
|---|---|---|---|
| Any three or more of | Mandatory elevated WC | Any three or more of | |
| Elevated WC or BMI | ≥90 cm (men) or ≥80 cm (women) | ≥90 cm (men) or ≥80 cm (women) | BMI ≥25 kg/m2 |
| Plus two or more of | |||
| Elevated FPG | ≥5.6 mmol/L or drug treatment for elevated blood glucose | ≥5.6 mmol/L or diagnosed diabetes | ≥6.1 mmol/L or drug treatment for elevated blood glucose |
| Elevated TGs | ≥1.7 mmol/L or drug treatment for elevated TGs | ≥1.7 mmol/L or drug treatment for elevated TGs | ≥1.7 mmol/L |
| Reduced HDL | <1 mmol/L (men) or <1.3 mmol/L (women) or drug treatment for reduced HDL | <1 mmol/L (men) or <1.3 mmol/L (women) or drug treatment for reduced HDL | <0.9 mmol/L (men) or <1.0 mmol/L (women) |
| Elevated BP | ≥130/85 mmHg or drug treatment for hypertension | ≥130/85 mmHg or drug treatment for hypertension | ≥140/90 mmHg or drug treatment for hypertension |
NCEP ATP III: National cholesterol education program-third adult treatment panel; IDF: International diabetes federation; CDS: Chinese diabetes society; WC: Waist circumference; BMI: Body mass index; FPG: Fasting plasma glucose; HDL: High-density lipoprotein; BP: Blood pressure; TG: Triglyceride.
Characteristics of the study population
| Variables | Men ( | Women ( | ||
|---|---|---|---|---|
| Age, years | 43.4 ± 12.6 | 43.5 ± 13.2 | 3.63 | <0.001 |
| WC, cm | 89.2 ± 9.0 | 77.0 ± 8.7 | 123.17 | <0.001 |
| BMI, kg/m2 | 25.4 ± 3.4 | 23.0 ± 3.3 | 63.49 | <0.001 |
| FPG, mmol/L | 5.5 ± 1.3 | 5.2 ± 1.1 | 23.02 | <0.001 |
| TG, mmol/L | 2.0 ± 1.7 | 1.3 ± 0.9 | 44.83 | <0.001 |
| HDL, mmol/L | 1.4 ± 0.4 | 1.6 ± 0.4 | −51.18 | <0.001 |
| SBP, mmHg | 124.1 ± 17.4 | 116.7 ± 19.1 | 37.04 | <0.001 |
| DBP, mmHg | 83.1 ± 11.2 | 76.5 ± 10.7 | 53.26 | <0.001 |
Data are expressed as mean ± SD. P value is for the comparison between men and women. WC: Waist circumference; BMI: Body mass index; FPG: Fasting plasma glucose; TG: Triglyceride; HDL: High-density lipoprotein; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; df: Degrees of freedom; SD: Standard deviation.
Prevalence of the individual components of the metabolic syndrome based on definitions of revised NCEP ATP III, IDF, and CDS criteria among employees in Northeast China
| Items | 95% | |||
|---|---|---|---|---|
| Men | Women | |||
| Elevated WC, ≥90 cm (men) and ≥80 cm (women) | 50.7 (50.0–51.5) | 35.9 (35.1–36.7) | 720.24 | <0.001 |
| Elevated BMI, BMI ≥5 kg/m2 | 54.7 (54.0–55.4) | 24.6 (23.8–25.3) | 3002.36 | <0.001 |
| Elevated FPG | ||||
| ≥5.6 mmol/L | 30.5 (30.0–31.2) | 17.8 (17.2–18.4) | 693.71 | <0.001 |
| ≥6.1 mmol/L | 15.2 (14.7–15.7) | 8.0 (7.6–8.5) | 380.82 | <0.001 |
| Elevated TG | ||||
| ≥1.7 mmol/L | 45.2 (44.5–45.9) | 20.2 (19.5–20.9) | 2223.49 | <0.001 |
| Reduced HDL | ||||
| <1.0 mmol/L (men) or <1.3 mmol/L (women) | 6.9 (6.5–7.2) | 19.7 (19.0–20.3) | 1231.47 | <0.001 |
| <0.9 mmol/L (men) or <1.0 mmol/L (women) | 4.4 (4.1–4.7) | 3.7 (3.4–4.1) | 9.42 | <0.001 |
| Elevated BP | ||||
| ≥130/85 mmHg | 45.2 (44.5–45.9) | 27.3 (26.6–28.1) | 1095.95 | <0.001 |
| ≥140/90 mmHg | 37.2 (36.6–37.9) | 21.2 (20.5–21.8) | 980.50 | <0.001 |
P value is for the comparison between men and women. NCEP ATP III: National cholesterol education program-third adult treatment panel; IDF: International diabetes federation; CDS: Chinese diabetes society; WC: Waist circumference; BMI: Body mass index; FPG: Fasting plasma glucose; TG: Triglyceride; HDL: High-density lipoprotein; BP: Blood pressure; df: Degrees of freedom; CI: Confidence interval.
Prevalence of the metabolic syndrome based on definitions of revised NCEP ATP III, IDF, and CDS criteria among employees in Northeast China
| Age groups, years | The metabolic syndrome prevalence (95% | |||
|---|---|---|---|---|
| Revised ATP III | IDF | CDS | ||
| All | ||||
| 18–29 | 4853 | 7.4 (6.6–8.1) | 6.8 (6.1–7.5) | 4.7 (4.1–5.3) |
| 30–44 | 13,351 | 20.1 (19.4–20.8) | 18.2 (17.5–18.8) | 14.2 (13.6–14.8) |
| 45–59 | 11,097 | 34.7 (33.8–35.6) | 30.9 (30.0–31.7) | 23.5 (22.7–24.3) |
| ≥60 | 3848 | 42.3 (40.8–43.9) | 38.4 (36.9–39.9) | 26.7 (25.3–28.1) |
| Total (crude) | 33,149 | 25.7 (25.2–26.2) | 23.1 (22.7–23.6) | 17.4 (17.0–17.8) |
| Total (age and sex-standardized) | 33,149 | 22.9 (22.0–23.8) | 20.6 (19.8–21.5) | 15.3 (14.6–16.1) |
| Men | ||||
| 18–29 | 2504 | 12.0 (10.8–13.3) | 11.4 (10.2–12.7) | 8.5 (7.4–9.6) |
| 30–44 | 8013 | 28.3 (27.4–29.3) | 25.9 (24.9–26.9) | 21.7 (20.8–22.6) |
| 45–59 | 6672 | 39.9 (38.7–41.0) | 35.4 (34.2–36.5) | 30.7 (29.6–31.8) |
| ≥60 | 2148 | 34.6 (32.6–36.6) | 30.2 (28.3–32.2) | 25.0 (23.2–26.9) |
| Subtotal (crude) | 19,337 | 30.9 (30.3–31.6) | 27.8 (27.1–28.4) | 23.5 (22.9–24.1) |
| Subtotal (age-standardized) | 19,337 | 27.1 (25.9–28.4) | 24.5 (23.3–25.7) | 20.4 (19.3–21.5) |
| Women | ||||
| 18–29 | 2349 | 2.4 (1.8–3.1) | 1.9 (1.3–2.4) | 0.6 (0.3–0.9) |
| 30–44 | 5338 | 7.7 (7.0–8.4) | 6.6 (6.0–7.3) | 3.0 (2.5–3.4) |
| 45–59 | 4425 | 27.0 (25.7–28.3) | 24.1 (22.8–25.4) | 12.7 (11.7–13.7) |
| ≥60 | 1700 | 52.1 (49.7–54.4) | 48.7 (46.3–51.1) | 28.7 (26.6–30.9) |
| Subtotal (crude) | 13,812 | 18.4 (17.8–19.1) | 16.6 (16.0–17.2) | 8.9 (8.4–9.3) |
| Subtotal (age-standardized) | 13,812 | 17.1 (16.0–18.1) | 15.4 (14.4–16.4) | 8.3 (7.5–9.1) |
NCEP ATP III: National cholesterol education program-third adult treatment panel; IDF: International diabetes federation; CDS: Chinese diabetes society; ATP III: Adult treatment panel III; CI: Confidence interval.